Contact the Department of Radiation Oncology

Contact us to make an appointment or to learn more about our programs.

Contact usRequest an appointment

Clinical trials are scientific studies in which new treatments are tested in patients to determine if they are effective and safe.

The Department of Radiation Oncology's clinical trials offer access to promising new therapies. Browse our clinical trials below, and click on the ClinicalTrials.gov number for more information.

Breast Program Trials
  • Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening
    • Goal: To compare the absolute volumes of the upper extremity using both the LymphaTech Scanner and Perometer in a cohort of patients with a history of invasive or in-situ carcinoma of the breast.
    • Principal Investigator: Alphonse Taghian, MD, PhD
    • Clinical Trials.gov Number: NCT02603341
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 724-4000 to make an appointment with Dr. Taghian to see if you meet the study criteria.
  • Screening For BCRL In Targeted Therapy For Breast Cancer
    • Goal: To track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer.
    • Principal Investigator: Alphonse Taghian, MD, PhD
    • Clinical Trials.gov Number: NCT05142800
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 724-4000 to make an appointment with Dr. Taghian to see if you meet the study criteria.
  • Proton versus Photon Ultrahypofractionated Radiation Therapy and Its Impact on Normal Tissue
    • Goal: To determine if accelerated PBT is associated with less myocardial fibrosis than accelerated XRT and measure cardiac function and cardiac injury after accelerated PBT compared to accelerated XRT.
    • Principal Investigator: Rachel Jimenez, MD
    • Clinical Trials.gov Number: NCT05912231
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 643-0591 to make an appointment with Dr. Jimenez to see if you meet the study criteria.
  • The Role of Losartan in the Prevention of Early Structural Changes Associated with Radiation-Induced Heart Failure
    • Goal: To determine if losartan prevents RT-induced myocardial fibrosis in BC patients receiving RT, which will be assessed by extracellular volume (ECV) evaluated by cardiac MRI at 6 months after RT.
    • Principal Investigator: Rachel Jimenez, MD
    • Clinical Trials.gov Number: NCT05607017
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 643-0591 to make an appointment with Dr. Jimenez to see if you meet the study criteria.
Central Nervous System Program Trials
  • Local Control, Quality of Life and Toxicities in Adults with Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
    • Goal: To see how well the tumor is responding to Proton Radiation up to 5 years after the participant receives it and how this type of radiation affects the quality of life as well as any type of side effect the participant may have after the radiation is administered.
    • Principal Investigator: Helen Shih, MD
    • ClinicalTrials.gov Number: NCT03286335
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 724-1298 to make an appointment with Dr. Shih to see if you meet the study criteria.
  • Phase I Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
    • Goal: Find out if using increased-dose intensity modulated proton therapy (IMPT) for treatment of Meningiomas will be more effective than the current treatment.
    • Principal Investigator: Helen Shih, MD
    • ClinicalTrials.gov Number: NCT02693990
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 724-1298 to make an appointment with Dr. Shih to see if you meet the study criteria.
  • Phase II Trial of Normal Tissue Sparing Whole Brain Radiation Therapy (NTSWBRT) in Patients with Brain Metastases
    • Goal: To determine whether further radiation dose sparing of nontarget normal tissues may (1) improve the quality of life and (2) reduce symptom burden of patients undergoing otherwise standard of care whole brain radiation therapy with hippocampal avoidance as assessed by FACT-Brain questionnaire.
    • Principal Investigator: Helen Shih, MD
    • Clinical Trials.gov Number: NCT05013892
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 724-1298 to make an appointment with Dr. Shih to see if you meet the study criteria.
Gastrointestinal Program Trials
  • Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
    • Goal: Study a combination of drugs with radiation therapy as a possible treatment for Colorectal Cancer and Pancreatic Cancers.
    • Principal Investigator: Theodore Hong, MD
    • ClinicalTrials.gov Number: NCT03104439
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 726-6050 to make an appointment with Dr. Hong to see if you meet the study criteria.
  • Radiation Therapy with Protons or Photons in Treating Patients with Liver Cancer
    • Goal: Study how well radiation therapy with protons works compared with photons in treating patients with liver cancer.
    • Principal Investigator: Theodore Hong, MD
    • ClinicalTrials.gov Number: NCT03186898
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 726-6050 to make an appointment with Dr. Hong to see if you meet the study criteria.
  • Specimens and Clinical Data Collection in Oncology patients
    • Goal: Establish a centralized and uniform process for the collection of clinical and patient-self reported information, biologic sample collection and storage, and comprehensive databasing to allow for a searchable clinical and biologic sample repository obtained from oncology patients undergoing or being evaluated for radiation therapy.
    • Principal Investigator: Jennifer Wo, MD
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 726-6050 to make an appointment with Dr. Wo to see if you meet the study criteria.
  • Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab in Adults with Medically Inoperable Stage I or IIA Non-Small Cell Lung Cancers
    • Goal: Assess the efficacy and safety of SBRT plus pembrolizumab in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).
    • Principal Investigator: Katie (Florence) Keane, MD (MGH Site PI)
    • Clinical Trials.gov Number: NCT03924869
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 726-5184 to make an appointment with Dr. Keane to see if you meet the study criteria.
  • Phase IB Study of Atezolizumab and Bevacizumab with SBRT for Unresectable Hepatocellular Carcinoma
    • Goal: Determine safety and tolerability of concurrent Atezolizumab and Bevacizumab with liver SBRT for unresectable hepatocellular cancer
    • Principal Investigator: Jennifer Wo, MD
    • ClinicalTrials.gov Number: NCT05096715
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 726-6050 to make an appointment with Dr. Wo to see if you meet the study criteria.
  • A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation or Pathologic Complete Response after Neoadjuvant Therapy for Rectal Cancer
    • Goal: Evaluating the utility of circulating tumor DNA (ctDNA) to predict the likelihood of either successful organ preservation or pathologic complete response (pCR) one year following completion of total neoadjuvant therapy (TNT).
    • Principal Investigator: Theodore S. Hong, MD
    • ClinicalTrials.gov Number: PENDING
    • MGH Location(s) Available: Main Campus (Boston), Mass General Cancer Center at Newton-Wellesley
    • How to Enroll: Please call (617) 726-6050 to make an appointment with Dr. Hong to see if you meet the study criteria.
  • Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
    • Goal: See how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer.
    • Principal Investigator: Katie (Florence) Keane, MD (MGH Site PI)
    • Clinical Trials.gov Number: NCT03801876
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 726-5184 to make an appointment with Dr. Keane to see if you meet the study criteria.
Genitourinary Program Trials
  • Bladder fiducial markers and multiparametric-MRI (mp-MRI) to optimize bladder chemo-radiotherapy
    • Goal: Determine whether mp-MRI can predict grossly occult disease and detect bladder tumor within and outside of the fiducial marker-area in patients electing bladder preserving tri-modal therapy improves targeting and decreases collateral high-dose radiation.
    • Principal Investigator: Jason Efstathiou, MD, DPhil
    • Clinical Trials.gov Number: NCT04442724
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 726-5866 to make an appointment with Dr. Efstathiou to see if you meet the study criteria.
  • Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE)
    • Goal: Compare metastasis-free survival (MFS) of salvage RT and GnRH agonist/antagonist vs. RT/ GnRH agonist/antagonist with apalutamide for patients with pathologic node-positive prostate cancer after radical prostatectomy with detectable PSA.
    • Principal Investigator: Jason Efstathiou, MD, DPhil
    • ClinicalTrials.gov Number: NCT04134260
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 726-5866 to make an appointment with Dr. Efstathiou to see if you meet the study criteria.
  • Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT)
    • Goal: De-Intensification: To determine whether men with NCCN high risk prostate cancer who are in the lower 2/3 of Decipher genomic risk (< 0.85) can be treated with 12 months ADT plus RT instead of 24 months ADT+RT and experience non-inferior metastasis-free survival. Intensification: To determine whether men with NCCN high risk prostate cancer who are in the upper 1/3 of Decipher genomic risk (>0.85) or have node-positive disease by conventional imaging (MRI or CT scan) will have a superior metastasis-free survival (MFS) through treatment intensification with apalutamide added to the standard of RT plus 24 month ADT
    • Principal Investigator: Jason Efstathiou, MD, DPhil
    • ClinicalTrials.gov Number: NCT04513717
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 726-5866 to make an appointment with Dr. Efstathiou to see if you meet the study criteria.
Gynecologic Program Trials
  • A phase 2 Study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma
    • Goal: Study how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma.
    • Principal Investigator: Andrea Russo, MD
    • Clinical Trials.gov Number: NCT04430699
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 643-9354 to make an appointment with Dr. Russo to see if you meet the study criteria.
  • The Vaginal Microbiome and Microenvironment in Predicting Radiation Treatment Response and Toxicity in Gynecologic Cancers
    • Goal: To understands the changes in vaginal microbiome and microenvironment that predict toxicity in patients with gynecologic cancers treated with radiation treatment.
    • Principal Investigator: Andrea Russo, MD
    • Clinical Trials.gov Number: N/A
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 643-9354 to make an appointment with Dr. Russo to see if you meet the study criteria.
Pediatric Radiation Oncology Trials
  • Phase II Study of Proton Radiation Therapy for Neuroblastoma
    • Goal: Evaluate the acute and late toxicities during and after proton radiation for patients with high-risk Neuroblastoma requiring radiation therapy.
    • Principal Investigator: Shannon MacDonald, MD
    • ClinicalTrials.gov Number: NCT02112617
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 724-1836 to make an appointment with Dr. MacDonald to see if your child meets the study criteria.
  • PPCR: Registry for Pediatric Patients Treated with Radiation Therapy
    • Goal: of this PPCR Registry is to utilize data to describe the population of pediatric patients being treated by proton radiation and report the patterns of care in this population.
    • Principal Investigator: Torunn Yock, MD
    • ClinicalTrials.gov Number: NCT01696721
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 724-1836 to make an appointment with Dr. Yock to see if your child meets the study criteria.
Thoracic Program Trials
  • Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
    • Goal: See how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer.
    • Principal Investigator: Katie (Florence) Keane, MD (MGH Site PI)
    • Clinical Trials.gov Number: NCT03801876
    • MGH Location(s) Available: Main Campus (Boston)
    • How to Enroll: Please call (617) 726-5184 to make an appointment with Dr. Keane to see if you meet the study criteria.

 

Leaders in Proton Therapy

Mass General has the only proton therapy site in all of New England, with two proton therapy centers.

Learn more